ASH 2024: Daratumumab cuts risk of progression by half in smouldering multiple myeloma
Patients at high risk for developing multiple myeloma who received the drug daratumumab for up…
Patients at high risk for developing multiple myeloma who received the drug daratumumab for up…
DREAMM-7 trial shows sustained overall survival benefit for the Blenrep (belantamab mandolin) combination versus the…
Among patients with previously untreated chronic lymphocytic leukemia (CLL), those who received a combination regimen…
Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest…
Researchers from Roswell Park Comprehensive Cancer Center, USA, presented compelling findings showcasing the significant benefits…
New data suggest that a plant-based diet rich in fibre could help to improve the…
Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel…
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus…
Patients with acute myeloid leukaemia who have lower education levels and lower income are less…
In early results from a non-randomised study, the biologic agent epcoritamab, which leverages patients’ immune…